ライフサイエンスコーパス: never smoker

1 a, and being an former smoker (compared to a never smoker).

2 ncluding 2433 current, 6518 former, and 6956 never smokers).

3 mer smoker or a current smoker compared to a never smoker.

4 as defined as ex-smoker, current smoker, and never smoker.

5 histologic types and lung cancer in ever and never smokers.

6 never smoked and a reference group of twelve never smokers.

7 smokers had similar risks for BCC and SCC as never smokers.

8 y (HR 1.38, 95% CI 1.04 to 1.83) compared to never smokers.

9 chocardiographic features when compared with never smokers.

10 s, respectively, and was observed even among never smokers.

11 s had a mean age of 61.5 years, and 47% were never smokers.

12 ore MT and poorer periodontal condition than never smokers.

13 s on CVD and mortality were only observed in never smokers.

14 were either attenuated or absent in past and never smokers.

15 take were present in both current/former and never smokers.

16 in tumors collected from current, past, and never smokers.

17 ent smokers is two to three times as high as never smokers.

18 s. never smokers, and 39 genes in former vs. never smokers.

19 9; 95% CI: 0.94, 1.76; p-trend = 0.04) among never smokers.

20 n and 1.71 (95% CI: 0.95, 3.09; p = 0.07) in never smokers.

21 among heavy smokers (mean 35 pack-years) and never smokers.

22 1, 2.9) younger than 50 y when compared with never smokers.

23 -12 Mental Component Scale scores similar to never smokers.

24 e similar angina levels and mental health as never smokers.

25 associated TF (MP-TF) activity compared with never smokers.

26 oncogenes among 89 lung adenocarcinomas from never smokers.

27 n 2010 revealing measurement bias in healthy never smokers.

28 atio, 1.21; 95% CI, 1.06-1.39) compared with never smokers.

29 centrations compared with those of asthmatic never smokers.

30 posity at any age was 14% overall and 21% in never smokers.

31 d 1.27 (95% CI: 1.12, 1.43; p = 0.002) among never smokers.

32 rent smokers, whereas no cases were noted in never smokers.

33 risk of initiation of cigarette smoking than never smokers.

34 ent implants placed in cigarette smokers and never smokers.

35 smokers had a higher risk of ALS compared to never smokers.

36 ts placed in cigarette smokers compared with never smokers.

37 tal implants placed in cigarette smokers and never smokers.

38 educed mortality and CVD risk but only among never smokers.

39 riable degrees of emphysema were observed in never smokers.

40 No notable associations were observed among never smokers.

41 ng greater opportunities for detection among never smokers.

42 ationship between ambient PM2.5 and LC among never smokers.

43 sites with a different contour pattern than never-smokers.

44 those with asthma (p=0.004) than in healthy never-smokers.

45 king cessation returned to levels seen among never-smokers.

46 n 14 mutations, 68% were women, and 36% were never-smokers.

47 fter 10-12 years the risk equates to that of never-smokers.

48 of former smokers becomes similar to that of never-smokers.

49 escribed as having stopped by choice) versus never-smokers.

50 st former smokers becomes similar to that of never-smokers.

51 a and IL-6 levels are higher in smokers than never-smokers.

52 were current smokers and 56% (n = 6013) were never-smokers.

53 methylation in smokers compared with that in never-smokers.

54 n both male and female smokers compared with never-smokers.

55 6 levels were comparable between smokers and never-smokers.

56 64.5% of patients were women, and 67.7% were never-smokers.

57 tal inflammation is worse among smokers than never-smokers.

58 ]) were significantly higher in smokers than never-smokers.

59 ructive pulmonary disease (COPD), even among never-smokers.

60 similar for FVC and persisted among lifetime never-smokers.

61 ified model (PLCOall2014) evaluated risks in never-smokers.

62 s a slight attenuation of the association in never-smokers.

63 er in former and current smokers, but not in never-smokers.

64 actinomycetemcomitans, and T. forsythia than never-smokers.

65 r mutation profiles were similar to European never-smokers.

66 ressed in smokers without COPD compared with never-smokers.

67 nicotine intake and subsequent PD risk among never-smokers.

68 comparing smokers with and without COPD, and never-smokers.

69 smokers or ex-smokers with otherwise similar never-smokers.

70 r failure rates and bone loss in smokers and never-smokers.

71 regardless of smoking history, including in never-smokers.

72 verty were risk factors for COPD, even among never-smokers.

73 eating was also a risk factor for COPD among never-smokers.

74 elerated lung function decline compared with never-smokers.

75 in nonsilicotics and in current, former, and never-smokers.

76 ctors that uniquely contribute to COPD among never-smokers.

77 eatest among those younger than 70 years and never-smokers.

78 tion and in patients with COPD compared with never-smokers.

79 its ratio to forced vital capacity (FVC) in never-smokers.

80 ation was 0.851 (95% CI = 0.840-0.862), with never smokers 0.806 (95% CI = 0.790-0.819), light smoker

81 for smokers [0.66 (95% CI: 0.43, 1.02)] and never smokers [0.65 (95% CI: 0.52, 0.81)].

82 -2.02]) and not significantly different from never smokers 1-1.9 years after cessation.

83 s nonusers of cannabis, adjusted for ever vs never smoker: 1.41; 95% CI, 1.09-1.83).

84 0 patients (screening cohort) encompassing 8 never-smokers, 10 smokers without airflow limitation, an

85 35%), compared with former smokers (19%) and never smokers (13%).

86 were 11 (95% confidence interval: 5.8-22) in never-smokers, 13 (6.2-29) in former smokers, and 18 (8.

87 ml; P = 0.002), which were not evident among never-smokers (-15.9 ml; P = 0.69 and -13.7 ml; P = 0.70

88 ividuals with a detailed smoking history (24 never-smokers, 16 smokers, and 8 ex-smokers).

89 ot significantly different between asthmatic never smokers (184 endotoxin units [EU]/mL; IQR, 91-310

90 Comparing former versus never smokers, 185 of the CpGs that differed between cur

91 , 5,691 (6%) had self-reported asthma (2,304 never-smokers, 2,467 former smokers, and 920 current smo

92 CI, 1.12-2.30; P = .009); and for current vs never smokers: 2.00 (95% CI, 1.22-3.28; P = .006).

93 ette smoking on the periodontium compared to never-smokers; (2) patterns of site-specific effects by

94 asured with a high-sensitivity assay in 3824 never smokers, 2341 former smokers, and 2550 current smo

95 Comparing current versus never smokers, 2623 cytosine-phosphate-guanine sites (Cp

96 g/L; interquartile range, 2.0-4.1 ng/L) than never smokers (3.2 ng/L; interquartile range, 2.2-4.7 ng

97 sion due to COPD were 8.6 (95% CI 5.3-14) in never smokers, 30 (22-41) in former smokers, and 43 (32-

98 L per year (95% CI 30.66-31.37) in sustained never-smokers, 34.97 mL per year (34.36-35.57) in former

99 Patients were primarily men (90%), were never-smokers (51%), and had performed oral sex (97%), w

100 penhagen City Heart Study in our study: 2199 never-smokers, 5435 ever-smokers, 158 with asthma, 320 w

101 first full-term pregnancy <30y of age (79%), never-smokers (56%) with body mass indexes (BMIs) of <29

102 n the Cardiovascular Health Study, 2556 were never-smokers, 629 current smokers, and 1297 former smok

103 Among the 16 never-smokers, 69% had an EGFR mutation compared with 29

104 d DNA methylation in lung adenocarcinoma (61 never smokers, 91 current smokers, and 238 former smoker

105 Among never smokers, a total vitamin D intake >/=400 IU/d was

106 Compared to never-smokers, accelerated FEV(1) decline was observed i

107 Lung adenocarcinomas from never smokers account for approximately 15 to 20% of all

108 Compared with never smokers, adjusted costs for the index hospitalizat

109 atio, 1.42; 95% CI, 1.28-1.58) compared with never smokers after adjustment for age and other potenti

110 h the risk of tooth loss approaching that of never smokers after approximately 10 to 20 y of cessatio

111 Current, former, and never-smokers aged 45 years from the 1960 U.S. birth coh

112 <1 year after smoking cessation compared to never smokers (aIRR, 1.66 [95% confidence interval {CI},

113 ure and assessed associations separately for never smokers and ever smokers.

114 Never smokers and ex-smokers with MS had similar mortali

115 MS had similar mortality rates compared with never smokers and ex-smokers without MS in the male Brit

116 rvival after PDAC compared to those who were never smokers and never drinkers.

117 The associations were stronger in never smokers and non-ICS users.

118 , and stronger associations were observed in never smokers and non-ICS users.

119 ers, and exsmokers) and 20 healthy subjects (never smokers and smokers) were recruited.

120 was more likely to be reported among female never smokers and those who had been exposed for >/=20 y

121 cer risk in any subgroup examined, including never smokers and women with body mass index (weight (kg

122 had worse HRQOL in all domains compared with never smokers and worse Short Form-12 Mental Component S

123 ts were more consistently significant in the never-smoker and non-alcohol drinking groups.

124 man bronchial epithelial cells isolated from never-smokers and in the airways of a novel, ovine large

125 When the cohort was restricted to never-smokers and to former smokers who had quit at leas

126 ion of individuals have zero exposure (e.g., never smokers) and among those exposed the variable has

127 ifferentially expressed genes in current vs. never smokers, and 39 genes in former vs. never smokers.

128 s showed generalizability across smokers and never smokers, and across ancestral groups.

129 The associations persisted in never smokers, and were strongest before age 60 years fo

130 form a sensitivity analysis in the subset of never-smokers, and these two probes are known to be stro

131 ls (50 patients with T2DM [25 smokers and 25 never-smokers] and 50 controls [25 smokers and 25 never-

132 , possibly adverse effects of e-cig vapor in never-smokers are not well understood.Objectives: To tes

133 In post hoc analyses among female never smokers, both PM2.5 (ORQ5 vs. Q1 = 1.79; 95% CI: 1

134 and current smokers was compared to that of never-smokers by use of mixed models adjusted for sociod

135 ivided into current smoker, past smoker, and never smoker categories.

136 However, when restricting to never smokers compared with nondrinkers, the hazard rati

137 analyze changes to the LTA4H-PGP pathway in never smokers, control smokers, COPD smokers, and COPD f

138 Compared with never smokers, current and past smokers showed a statist

139 Compared with never smokers, current smokers had greater left ventricu

140 Compared with never smokers, current smokers had significantly lower r

141 and never-smokers (P = 0.67).Conclusions: SZ never-smokers demonstrated no increased risk of COPD, re

142 besity, aHR = 0.66, 95% CI: 0.48, 0.92), but never-smokers did not (overweight, aHR = 1.41, 95% CI: 0

143 sia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutation

144 tio of 2.76 (95% CI 2.71-2.81) compared with never-smokers, even though 44% (37,240/85,256) of the ba

145 City Heart Study into six subgroups: healthy never-smokers, ever-smokers without asthma and COPD, tho

146 Among never-smokers, fewer teeth/sites were affected with PD >

147 ger for other non-small cell lung cancer and never smokers for the "American/Western" pattern.

148 However, relative to never smokers, former smokers' CVD risk remained signifi

149 Compared with never-smokers, former smokers as a group had similar ris

150 ion >=0.1 g (gravity)) in smokers but not in never smokers: FVC differences for 10 min increase in MV

151 Cigarette smokers (group 1) and never smokers (group 2) with adjacent dental implants we

152 ulted in 678 matched pairs in the current vs never smoker grouping and 945 pairs in the former vs nev

153 oker grouping and 945 pairs in the former vs never smoker grouping.

154 high FEV1 from each of the heavy smoker and never smoker groups.

155 bservational analyses showed that current vs never smokers had lower risk of hay fever (odds ratio (O

156 The majority (98.6%) of never smokers had nondetectable cotinine.

157 Asian never-smokers had lung cancer signatures distinct from t

158 None of 65,711 PLCO never-smokers had PLCO(m2012) risk >/= 0.0151.

159 e hypothesis that, in individuals with COPD, never smokers have different characteristics and less se

160 Compared with never smokers, health care costs during the first year a

161 In never smokers, HIV was not associated with an increased

162 colectomy when comparing current smokers to never smokers (HR 0.98, 95% CI 0.67 to 1.44).

163 e need for surgery when comparing former and never smokers (HR 1.11, 95% CI 0.95 to 1.30).

164 sed risk of intestinal resection compared to never smokers (HR 1.27, 95% CI 1.08 to 1.49); however, t

165 found with respiratory mortality only among never smokers (HR = 1.27; 95% CI: 1.03, 1.56).

166 although the association was stronger among never-smokers (HR, 1.61; 95% CI, 1.01 to 2.57; P trend =

167 (95% CI: 0.94, 1.07) based on 2,215 cases in never smokers; HR=1.10 (95% CI: 1.01, 1.19) based on 1,0

168 7 was also associated with lung cancer among never smokers in the GENEVA dataset.

169 iated with lung cancer in uranium miners and never smokers in two external study populations.

170 on and comparing smokers, former smokers and never smokers in two Swedish cohorts, differing for know

171 ad worse periodontal status than smokers and never-smokers in the control group (P <0.05).

172 elerated lung function decline compared with never-smokers, including among those without prevalent l

173 is that the increase of lung cancer in Asian never-smokers is due to environmental factors such as se

174 xpiratory Flow, MMEF25-75%), AFP and CEA for never smokers, light and never smokers with cancer risks

175 e ex-smokers and smokers classified with the never-smoker-like cluster.

176 asing sputum endotoxin concentrations in the never smokers (linear regression alpha = .05, Spearman r

177 In never smokers, low 25(OH)D levels were associated with m

178 with advanced lung cancer who had clinical (never-smokers [<100 cigarettes per lifetime] or former l

179 ed in 3/89 tested tumors and 2/64 additional never smoker lung adenocarcinoma samples.

180 lop strategies for management of early stage never-smoker lung adenocarcinoma.

181 cavity cancer, we observed no association in never smokers (lung 0.99, 0.93-1.05; oral cavity 1.07, 0

182 Never-smoker males drinking </=1 glass/week had signific

183 Forty current smokers and 40 never-smokers, matched for age, sex, and mean PD of samp

184 Results Thirty-one healthy never-smokers (mean age, 24.3 years +/- 4.3; 14 women) w

185 buminuria measurement was 60 years, 51% were never-smokers, median albuminuria was 5.6 mg/g, and mean

186 oth urban and rural young men) had twice the never-smoker mortality rate (RR 1.98, 1.79-2.19, approac

187 th chronic obstructive pulmonary disease are never-smokers, most genetic susceptibility studies have

188 0.63; 95%CI = 0.41-0.97; P trend = 0.03) or never smokers (n = 308, HR = 0.58; 95%CI = 0.37-0.91; P

189 reased risk of ischemic events compared with never smokers (n = 4,135; hazard ratio [HR]: 1.24 [95% c

190 rs (n=69 [9%]), exsmokers (n=210 [28%]), and never smokers (n=461 [62%]) with severe asthma (n=760) r

191 ts were categorized as current, previous, or never smokers (NS) at listing for LT.

192 ts with type-2 diabetes mellitus (T2DM) than never-smokers (NS) without T2DM.

193 vaping electronic cigarettes (group 2), and never-smokers (NSs) (group 3).

194 iate Cox regression models, as compared with never smokers of the same sex, male ever smokers had a 3

195 e association studies were performed in 5070 never-smokers of the identification cohort LifeLines, an

196 er-smokers; the associations were evident in never smokers only at activity levels above the conventi

197 eports do not provide separate estimates for never smokers or for blacks, who incongruously have lowe

198 tients into two categories of either all the never-smokers or all the smokers or ex-smokers.

199 rsely associated with overall lung cancer in never smokers (OR = 0.50; P = 0.02).

200 ociation of rs660895-(AG+GG) with PD seen in never smokers (OR = 0.64, p < 0.001) disappeared among e

201 ma (OR = 1.17, 1.01-1.35) and lung cancer in never smokers (OR = 1.56, 1.05-2.30).

202 l [CI]: 1.3 to 2.4; P = 0.002) as well as in never-smokers (OR: 2.0, 95% CI: 1.2 to 3.5; P = 0.01).

203 1.11 to 1.69) comparing current smokers with never smokers ( P = .003).

204 5.3-10.0) years earlier, respectively, than never smokers (P < .001 for both).

205 43; 95% CI: 0.23, 0.84; P = 0.01) but not in never smokers (P = 0.8).

206 gnificantly lower in current smokers than in never smokers (P<0.001).

207 causes of low FEV1 between heavy smokers and never smokers (p=2.29 x 10(-16)) and between individuals

208 and women had 30% lower levels compared with never-smokers (P < 0.001 for both).

209 d IL-6 levels were higher among smokers than never-smokers (P <0.05).

210 ty did not differ between former smokers and never-smokers (P = 0.67).Conclusions: SZ never-smokers d

211 LA and mortality tended to be stronger among never-smokers (P values for interaction 0.06 and 0.01, r

212 n COPD (p=0.003), and the decline in healthy never-smokers (p<0.0001).

213 decline of 20.9 mL (1.2) per year in healthy never-smokers (p=0.19).

214 was associated with lower CHD risk by 12% in never-smokers (P=1.3x10(-16)) in comparison with 5% in e

215 The current study was based on never-smoker participants from 2 large prospective cohor

216 er-specific reference equations from healthy never smokers participating in 1991, 2002, and 2010 to d

217 ation approaches for overall survival in 327 never smoker patients with NSCLC from The University of

218 is the most dominant type of lung cancer in never-smoker patients.

219 were higher in lung tumors from smokers than never-smokers, pointing toward the mutagenic activity of

220 Among 3,757 never smokers, probable PTSD at baseline was associated

221 pausal breast cancer 0.89, 0.86-0.92) and in never-smokers (prostate 0.96, 0.93-0.99; premenopausal b

222 extraction did not decrease to the level of never smokers (rate ratio, 1.13; 95% CI, 1.04-1.24).

223 There were 313 (42.5%) never-smokers (reference group), 92 (12.5%) passive nons

224 among former smokers was similar to that for never smokers, regardless of time since quitting.

225 l in current, recent ex-, long-term ex-, and never-smokers, respectively.

226 (current smokers of >/=15 cigarettes/day vs. never smokers RR, 1.26; 95% CI, 1.23-1.30) and obesity (

227 Among never-smokers, rural residence was also associated with

228 , the high incidence of lung cancer in Asian never-smokers seems unlikely to be due to second-hand sm

229 ntifying screenees, and to determine whether never-smokers should be screened.

230 Currently, never-smokers should not be screened.

231 Relative to never smokers, smokers who maintained a consistent CPD h

232 we phenotyped peripheral blood NK cells from never smokers, smokers, and COPD patients and employed a

233 Sixty-nine asthmatic patients (never smokers, smokers, and exsmokers) and 20 healthy su

234 ed and localized BAFF expression in lungs of never-smokers, smokers without COPD, and patients with C

235 alveolar epithelial type II (ATII) cells of never-smokers, smokers, patients with COPD, and two expe

236 We enrolled 34 never-smoker subjects with nonsevere asthma.

237 fewer skin examinations and procedures than never smokers, suggesting greater opportunities for dete

238 l corticosteroids, particularly in asthmatic never smokers, suggests that airway endotoxin might cont

239 xpression confers stronger CHD protection in never-smokers than in ever-smokers.

240 Compared with never smokers, the multivariable hazard ratios in light

241 Compared with never smokers, the pooled RR from ten studies with 1 086

242 ent smoking and diabetes risk: compared with never smokers, the RRs were 1.21 (1.10-1.33) for light s

243 Compared with never-smokers, the all-cause mortality RR was highest in

244 recent ex-smokers than in long-term ex- and never-smokers; the associations were evident in never sm

245 Among never smokers there was also no evidence of an associati

246 life expectancy, respectively, compared with never smokers; those who quit smoking upon entering care

247 reast cancer diagnosis were more likely than never smokers to die of breast cancer (HR, 1.25; 95% CI,

248 smoke after diagnosis were more likely than never smokers to die of breast cancer (HR, 1.72; 95% CI,

249 In healthy never smokers, ultrasonic spirometers record lower lung

250 te-specific effects by age among current and never-smokers using contour maps.

251 mance status (0-1 vs 2), and smoking status (never-smoker vs ever-smoker).

252 5 and PM10 may increase PD risk among female never smokers warrants further investigation.

253 2.8, and the ratio for former smokers versus never smokers was 1.0-1.8, depending on cessation age.

254 ity risk for current smokers versus that for never smokers was 2.8, and the ratio for former smokers

255 n, the difference in IOP between current and never smokers was the highest in the fourth decade, rega

256 D in LSOCA was smoking; the relative risk vs never-smokers was 3.4 for former smokers (95% confidence

257 esults: No difference between SZ and control never-smokers was seen.

258 status (current smokers, former smokers, and never smokers) was performed at Mayo Clinic in Rochester

259 7 smokers with normal lung function, and 245 never-smokers, we measured a large number of clinical pa

260 asthma and 45 healthy controls [smokers and never smokers], we measured urinary tetranor prostagland

261 n current smokers and ex-smokers relative to never smokers were 2.70 (95% CI 1.59 to 4.58, p<0.001) a

262 f the CpGs that differed between current and never smokers were significant P<1x10(-7) (2623 CpGs at

263 -smokers] and 50 controls [25 smokers and 25 never-smokers]) were included.

264 2 mL per year (95% CI 1.24-2.40) compared to never-smokers, which was approximately 20% of the effect

265 never smokers with no family history of PD, never smokers who did have a family history had an odds

266 c factors that influence overall survival in never smokers who have non-small cell lung carcinoma (NS

267 of COPD, with adjusted PRs ranging from 1.5 (never smoker with 1 to 5 teeth removed) to 6.5 (current

268 cipants), and 1.22 (1.10-1.35) for comparing never smokers with and without exposure to passive smoke

269 In 108 smokers and never smokers with asthma and 45 healthy controls [smoke

270 eased in smokers with asthma and differ from never smokers with asthma.

271 157) vs 192 (91, 301) pg/ml, P = 0.001 than never smokers with asthma.

272 %), AFP and CEA for never smokers, light and never smokers with cancer risks as high as those within

273 Compared with never smokers with no family history of PD, never smoker

274 Compared with never smokers with no teeth removed, all combinations of

275 Relative to a common reference group of never smokers with the lowest nitrate exposures, associa

276 y IL-1beta and IL-6 levels among smokers and never-smokers with and without prediabetes (controls).

277 ion levels were comparable among smokers and never-smokers with and without T2DM.

278 al inflammatory conditions among smokers and never-smokers with and without T2DM.

279 Never-smokers with asthma had an increased risk of asthm

280 the subgingival microbiota of smokers versus never-smokers with chronic periodontitis and matched pro

281 he obesity paradox differs between ever- and never-smokers with COPD, 1,723 adult participants with t

282 obesity paradox appeared to be absent among never-smokers with COPD.

283 for mortality at ages 30-69 years, comparing never-smokers with current smokers by age they started s

284 he serum and GCF MCP-1 levels of smokers and never-smokers with periodontitis and compare them with t

285 turned and oxidized implants in smokers and never-smokers with periodontitis.

286 terleukin (IL)-1beta and IL-6 in smokers and never-smokers with prediabetes remains uninvestigated.

287 L-6 levels were comparable among smokers and never-smokers with prediabetes.

288 Never-smokers with T2DM had worse periodontal status tha

289 parameters were comparable among smokers and never-smokers with T2DM.

290 conditions are comparable among smokers and never-smokers with T2DM.

291 ose methylation reverts to levels typical of never smokers within decades after smoking cessation, an

292 Center workers in New York, including 6,133 never smokers without a previous diagnosis of asthma.

293 Of the 6,133 never smokers without asthma, 3,757 (61.3%) completed a

294 val = 1.19-1.72), with similar results among never smokers without asthma.

295 43 (32-59) in current smokers compared with never smokers without COPD.

296 Compared with never-smokers without asthma, individuals with asthma ha

297 Among individuals with asthma compared with never-smokers without asthma, multivariable adjusted haz

298 sease III/IV) compared with both smokers and never-smokers without COPD.

299 14.74 (10.06-21.59) in asthma compared with never-smokers without lung disease (all p<0.0001).

300 Compared with parous never smokers, women who had smoked for more than 20 pac

301 Inverse associations were also seen in never-smokers, younger participants (<55 years), and tho